GlassScriptPhysician profile
Nancy C Anderson
NPI 1699734699
$1,099.53
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $263 · 2022: $315 · 2023: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $276 · Food and Beverage: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $275.94 |
| Food and Beverage | $245.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $294.16 | 2023 | Xtandi |
| Silk Road Medical, INC. | $175.74 | 2021 | |
| Incyte Corporation | $149.57 | 2022-2023 | Jakafi |
| Seagen INC. | $99.00 | 2022 | |
| Abbvie INC. | $87.50 | 2021 | |
| Merck Sharp & Dohme LLC | $64.17 | 2022-2023 | Keytruda |
| Edwards Lifesciences Corporation | $43.75 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Pfizer INC. | $27.72 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $24.12 | 2023 | Calquence |
| Amgen INC. | $19.82 | 2023 | Kyprolis |
| Janssen Biotech, INC. | $18.95 | 2023 | Darzalex |
| Eagle Pharmaceuticals, INC. | $18.63 | 2022 | |
| Deciphera Pharmaceuticals INC. | $18.44 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.17 | 2023 | |
| Coherus Oncology, INC. | $15.22 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $12.56 | 2022 | |
| Glaxosmithkline, LLC. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.